Retrovirus reverse transcriptases containing a modified YXDD motif

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 3, 2005, Pages 169-182

  Sharma, Prem L ^a   Nurpeisov, Viktoria ^a   Schinazi, Raymond F ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

HIV 1; Mutation; Reverse transcriptase (RT); YXDD motif

Indexed keywords

ABACAVIR; ADEFOVIR; AMINO ACID; DELAVIRDINE; EMTRICITABINE; LAMIVUDINE; MUTANT PROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME ACTIVITY; FELINE IMMUNODEFICIENCY VIRUS; GENE REPRESSION; GENETIC CONSERVATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DOCUMENTATION; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN MOTIF; RETROVIRUS; RETROVIRUS INFECTION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 27244447331     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600303     Document Type: Review

References (103)

1. Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M; CNA3002 International Study Team (2002) M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 16:1686-1689.
2. Argos P (1988) A sequence motif in many polymerases. Nucleic Acids Research 6:3831-3843.
3. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH & Berkhout B (1996) Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO Journal 15:4040-4049.
4. Barber AM, Hizi A, Maizel JV & Hughes SH (1990) HIV-1 reverse transcriptase: structure predictions for the polymerase domain. AIDS Research & Human Retroviruses 6:1061-1072.
5. Berkhout B, Verhoef K, van Wamel JL & Back NK (1999) Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. Journal of Virology 73:1138-1145.
6. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA & Cameron JM (1993) High level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 37:2231-2234.
7. Boyer PL & Hughes SH (1995) Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 39:1624-1628.
8. Boyer PL, Sarafianos SG, Arnold E & Hughes SH (2001a) Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. Journal of Virology 75:4832-4842.
9. Boyer PL, Gao H-Q, Clark PK, Sarafianos SG, Arnold E & Hughes SH (2001b) YADD mutants of human immunodeficiency virus type 1 and moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro. Journal of Virology 75:6321-6328.
10. Boyer PL, Sarafianos SG, Arnold E & Hughes SH (2002) The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. Journal of Virology 76:3248-3256.
11. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP & Wainberg MA (2002) Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. Journal of Virology 76:1753-1761.
12. Brenner, B, Routy J-P, Quan Y, Moisi D, Oliveira M, Turner D, Wainberg MA & co-investigators of the Quebec Primary Infection Study (2004) Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18:1653-1660.
13. Briones C, Perez-Olmeda M, Rodriguez C, del Romero J, Hertogs K & Soriano V (2001) Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. Journal of Acquired Immune Deficiency Syndromes 26:145-150.
14. Catucci M, Venturi G, Romano L, Riccio ML, De Milito A, Valensin PE & Zazzi M (1999) Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. Journal of Acquired Immune Deficiency Syndromes 21:203-208.
15. Choo H, Chong Y, Choi Y, Mathew J, Schinazi RF & Chu CK (2003) Synthesis, anti-HIV activity, and molecular mechanism of drug resistance of L-2′,3′-didehydro-2′,3′-dideoxy-2′-fluoro- 4′-thionucleosides. Journal of Medicinal Chemistry 46:389-398.
16. Clarke JR, Braganza R, Mirza A, Stainsby C, Ait-Khaled M, Wright A, Lyall H, Parker D, McClure MO, Weber JN & Taylor GP (1999) Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. Journal of Medical Virology 59:364-368.
17. Coffin JM (1995) HIV population dynamics in vivo; implications for genetic variation, pathogenesis and therapy. Science 267:483-489.
18. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, Selmi B, Boretto J & Canard B (2004) Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. Journal of Biological Chemistry 279:509-516.
19. Devereux HL, Youle M, Johnson MA & Loveday C (1999) Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13:F123-F127.
20. Diallo K, Brenner B, Oliveira M, Moisi D, Detorio M, Gotte M & Wainberg MA (2003) The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrobial Agents & Chemotherapy 47:2376-2379.
21. Ding J, Das K, Hsiou Y, Sarafianos SG, Clark AD Jr, Jacoba-Molina A, Tantillo C, Hughes SH & Arnold E (1998) Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. Journal of Molecular Biology 11:1095-1110.
22. Donahue PR, Hoover EA, Beltz GA, Riedel N, Hirsch VM, Overbaugh J & Mullins JI (1988) Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia virus. Journal of Virology 62:722-731.
23. Drosopoulos WC & Prasad VR (1998) Increased misincorporation tidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro. Journal of Virology 72:4224-4230.
24. Feng JY & Anderson KS (1999) Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 38:9440-9448.
25. Gao HQ, Boyer PL, Sarafianos SG, Arnold E & Hughes SH (2000) The role of steric hinderance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. Journal of Molecular Biology 300:403-418.
26. Gotte M, Arion D, Parniak MA & Wainberg MA (2000) The M184V mutation in the reverse transcriptase of human immunodeficiency virus type1 impairs rescue of chain-terminated DNA synthesis. Journal of Virology 74:3579-3585.
27. Halvas EK, Svarovskaia ES & Pathak VK (2000a) Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelity. Journal of Virology 74:312-319.
28. Halvas EK, Svarovskaia ES, Freed EO & Pathak VK (2000b) Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2′,3′-dideoxy-3′-thiacytidine. Journal of Virology 74:6669-6674.
29. Hamburgh ME, Drosopoulos WC & Prasad VR (1998) The influence of 3TC-resistance mutations E89G and M184V in the human immunodeficiency virus reverse transcriptase on mispair extension efficiency. Nucleic Acids Research 26:4389-4394.
30. Harrer E, Harrer T, Barbosa P, Feinberg M, Johnson RP, Buchbinder S & Walker BD (1996) Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. Journal of Infectious Diseases 173:476-479.
31. Harris DP, Yadav NS & Pandey VN (1998) Loss of polymerase activity due to Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus type-1 reverse transcriptase is compensated by Met to Val substitution within the same motif. Biochemistry 37:9630-9640.
32. Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR & Wainberg MA (1997) Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Research 25:4532-4536.
33. Huang H, Chopra R, Verdin GF & Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 RT: implications for drug resistance. Science 282:1669-1675.
34. Isaguliants MG, Petrakova N, Zuber B, Pokrovskaya K, Gizatullin R & Kostyuk DA (2000) DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge. Intervirology 43:288-293.
35. Johnson MS, McClure MA, Feng DF, Gray J & Doolittle RF (1986) Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonverbal enzymes. Proceedings of the National Academy of Sciences, USA 83:7648-7652.
36. Jonckheere HM, Witvrouw E, De Clercq E & Anne J (1998) Lamivudine resistant of HIV type 1 does not delay development of resistance to non-nucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild type HIV type 1. AIDS Research & Human Retroviruses 14:249-253.
37. Julias JG, Boyer PL, McWilliams MJ, Alvord WG & Hughes SH (2004) Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology 322:13-21.
38. Kamer G & Argos P (1984) Primary structural comparison of RNA-dependent polymerases from plant, animal, and bacterial viruses. Nucleic Acids Research 12:7269-7282.
39. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M & Purdon S (2000) The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS 14:781-789.
40. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C & Purdon S; CNA3002 European Study Team (2001) Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. HIV Medicine 2:27-34.
41. Kaushik N, Singh K, Alluru I & Modak MJ (1999) Tyrosine 222, a member of the YXDD motif of MuLV RT, is catalytically essential and is a major component of fidelity center. Biochemistry 2:2617-2627.
42. Kaushik N, Chowdhury K, Pandey VN & Modak MJ (2000) Valine of the YVDD motif of moloney murine leukemia virus reverse transcriptase: role in the fidelity of DNA synthesis. Biochemistry 39:5155-5165.
43. Kavlick MF, Shirasaka T, Kojima E, Pluda JM, Hui F Jr, Yarchoan R & Mitsuya H (1995) Genotypic and phenotypic characterization from HIV-1 from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antiviral Research 28:133-146.
44. Larder BA, Purifoy DJ, Powell KL & Darby G (1987) Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature 327:716-717.
45. Larder BA, Kemp SD & Purifoy DJM (1989) Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proceedings of the National Academy of Sciences, USA 86:4803-4807.
46. Larder BA, Kemp SD & Harrigan PR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
47. Le Grice SFJ, Naas T, Wohlgensinger B & Schartz O (1991) Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO Journal 10:3905-3911.
48. Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD & Richman DD (1999) Reduced antiretroviral drug susceptibility among patients with primary HIV infection. Journal of the American Medical Association 282:1142-1149.
49. Lowe DM, Parmar V, Kemp SD & Larder BA (1991) Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase. FEBS Letters 282:231-234.
50. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, Lachassine E, Barret B, Chaix ML, Bongain A, Ciraru-Vigneron N, Crenn-Hebert C, Delfraissy JF, Rouzioux C, Mayaux MJ & Blanche S; Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group (2001) Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. Journal of the American Medical Association 285:2083-2093.
51. Mansky LM & Temin HM (1994) Lower mutation rate of bovine leukemia virus relative to that of spleen necrosis virus. Journal of Virology 68:494-499.
52. Mansky LM & Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of reverse transcriptase. Journal of Virology 69:5087-5094.
53. Masquelier B, Descamps D, Carriere I, Ferchal F, Collin G, Denayrolles M, Ruffault A, Chanzy B, Izopet J, Buffet-Janvresse C, Schmitt MP, Race E, Fleury HJ, Aboulker JP, Yeni P & Brun-Vézinet F (1999) Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study. Antiviral Therapy 4:69-77.
54. McCrackin M, Stevenson MA & McBroom DG (2001) In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants. American Journal of Veterinary Research 62:588-594.
55. Miller V, Sturmer M, Staszewski S, Groschel B, Hertogs K, de Bethune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD & Larder BA (1998) The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 12:705-712.
56. Miller MD, Anton KE, Mulato AS, Lamy PD & Cherrington JM (1999) Human immunodeficiency virus type-1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. Journal of Infectious Diseases 79:92-100.
57. Miller MD, Margot NA, Hertogs K, Larder B & Miller V (2000) Anti-HIV activity profile of tenofovir (PMPA) against a panel of nucleoside-resistant clinical samples. Antiviral Therapy 5:4-5.
58. Miller V, Stark T, Loeliger AE & Lange JM (2002) The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Medicine 3:135-145.
59. Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vézinet F & Calvez V (2001) Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antiviral Therapy 6:179-183.
60. Murry JP, Higgins J, Matthews TB, Huang VY, Van Rompay KK, Pedersen NC & North TW (2003) Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. Journal of Virology 77:1120-1130.
61. Naeger LK, Margot NA & Miller MD (2001) Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator, removal, and viral replication. Antiviral Therapy 6:115-126.
62. Newstein MC & Desrosiers RC (2001) Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in rhesus monkeys. Journal of Infectious Diseases 184:1262-1267.
63. Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danner S, Keulen W, de Groot T & Boucher CA (1997) Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. Journal of Infectious Diseases 176:398-405.
64. Pandey VN, Kaushik N, Pege N, Sarafianos SG, Yadav PNS & Modak MJ (1996) Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in polymerase function and fidelity of DNA synthesis. Biochemistry 35:2168-2179.
65. Parthasarathi SA, Echavarria YV, Ron Y, Preston BD & JP Dougherty (1995) Genetic rearrangements occurring during a single cycle of murine leukemia virus vector replication: characterization and implication. Journal of Virology 69:7991-8000.
66. Pathak VK & Temin HM (1990a) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hot spots in a retroviral shuttle vector after a single replication cycle: substitutions, frame shifts and hypermutations. Proceedings of the National Academy of Sciences, USA 87:6019-6023.
67. Pathak VK & Temin HM (1990b) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hot spots in a retroviral shuttle vector after a single replication cycle: deletions and deletions with insertions. Proceedings of the National Academy Sciences, USA 87:6024-6028.
68. Petrella M, Oliveira M, Moisi D, Detorio M, Brenner BG & Wainberg M (2004) Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrobial Agents & Chemotherapy 48:4189-4194.
69. Picchio GR, Valdez H, Sabbe R, Landay AL, Kuritzkes DR, Lederman MM & Mosier DE (2000) Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. Journal of Acquired Immune Deficiency Syndromes 25:289-295.
70. Pillay D (2001) The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population. Antiviral Therapy 6:15-24.
71. Poch O, Sauvaget I, Delarue M & Tordo N (1989) Identification of four conserved motifs among the RNA dependent polymerase encoding elements. EMBO Journal 8:3867-3874.
72. Quan Y, Brenner BG, Oliveira M & Wainberg MA (2003) Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrobial Agents & Chemotherapy 47:747-754.
73. Rezende LF, Curr K, Ueno T, Mitsuya H & Prasad VR (1998) The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity. Journal of Virology 72:2890-2895.
74. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D & Routy JP (2000) Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec primary infection study. AIDS 14:F17-F23.
75. Samri A, Haas G, Duntze J, Bouley JM, Calvez V, Katlama C & Autran B (2000) Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. Journal of Virology 74:9306-9312.
76. Sarafianos S, Das K, Clark AD Jr, Ding J, Boyer PL, Hughes SH & Arnold E (1999) 3TC (lamivudine) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proceedings of the National Academy of Sciences, USA 96:10027-10032.
77. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ & Mellors JW (1993) Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents & Chemotherapy 37:875-881.
78. Schmitt M, Harrer E, Goldwich A, Bauerle M, Graedner I, Kalden JR & Harrer T (2000) Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 14:653-658.
79. Sharma PL & Crumpacker CS (1999) Decreased processivity of RT containing a didanosine-selected RT mutation: comparative evaluation of the effect of RT mutations Leu74Val and Met184Val on viral fitness and RT processivitv. Journal of Virology 73:8448-8456.
80. Shinnick TM, Lerner RA & Sutcliffe JG (1981) Nucleotide sequence of moloney murine leukemia virus. Nature 293:543-548.
81. Smith RA, Remington KM, Lloyd RM, Schinazi RF & North TW (1997) A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. Journal of Virology 71:2357-2362.
82. Svarovskaia ES, Delviks KA, Hwang CK & Pathak VK (2000) Structural determinants of murine leukemia virus reverse transcriptase that affects the frequency of template switching. Journal of Virology 74:7171-7178.
83. Tanuri A, Caridea E, Dantas MC, Morgado MG, Mello DL, Borges S, Tavares M, Ferreira SB, Santoro-Lopes G, Martins CR, Esteves AL, Diaz RS, Andreo SM, Ferreira LA, Rodrigues R, Reuter T, Cavalcanti AM, de Oliveira SM, de Barbosa HB, Teixeira PR & Chequer PN (2002) Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART Journal of Clinical Virology 25:39-46.
84. Temin HM (1993) Retrovirus variation and reverse transcription: abnormal strand transfer results in retrovirus genetic variation. Proceedings of the National Academy of Sciences, USA 90:6900-6903.
85. Tian H, Whitcomb JM, Limoli K, Wrin T, Winslow G, Parkin N, Smith D, Lie YS, Bakthiari M, Shugarts D, Schooley RT, Kuritzkes D & Petropoulos CJ (1998) Zidovudine/lamivudine co-resistance is preceded by a transient period of zidovudine hypersensitivity. Antiviral Therapy 3(Suppl 1):22-23.
86. Tisdale M, Kemp SD, Parry N & Larder BA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 90:5653-5656.
87. Turner D, Brenner BG, Routy JP, Petrella M & Wainberg MA (2004) Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiology 27:31-39.
88. Van Rompay KK, Matthews TB, Higgins J, Canfield DR, Tarara RP, Wainberg MA, Schinazi RF, Pedersen NC & North TW (2002) Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. Journal of Virology 76:6083-6092.
89. Verhofstede C, Wanzeele FV, Der Gucht BV, Cabooter ND & Plum J (1999) Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13:2541-2546.
90. Wakefield JK, Jablonski SA & Morrow CD (1992) In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. Journal of Virology 66:6806-6812.
91. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooky TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N & Cameron J (1995) Development of HIV-1 resistance to (-)-2′,3′-dideoxy-3′-thiacytidine in patients with AIDS or AIDS-related complex. AIDS 9:351-357.
92. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G & Prasad VR (1996a) Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285.
93. Wainberg MA, Lewis L, Salomon H, Gu Z, Keller A, Cammack N, Goldsmith J, Church J, Spira B, Wheeler S & Pizzo P (1996b) Resistance to (-)-2′,3′-dideoxy-3′-thiacytidine (3TC) in HIV-1 isolated from pediatric patients. Antiviral Therapy 1:98-104.
94. Wainberg MA, Hsu M, Gu Z, Borkow G & Parniak MA (1996c) Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10(Suppl 5):S3-S10.
95. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM (1999) In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 4:87-94.
96. Wainberg MA (2004) The impact of the M184V substitution on drug resistance and viral fitness. Expert Review of Anti-Infective Therapy 2:147-151.
97. Wei X, Liang C, Gotte M & Wainberg MA (2002) The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS 16:2391-2398.
98. Wei X, Liang C, Gotte M & Wainberg MA (2003) Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 311:202-212.
99. Whitney JB, Oliveira M, Detorio M, Guan Y & Wainberg MA (2002) The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus. Journal of Virology 76:8958-8962.
100. Wilson JE, Aulabaugh A, Caligan B, McPherson S, Wakefield JK, Jablonski S, Morrow CD, Reardon JE & Furman PA (1996) Human immunodeficiency virus type-1 reverse transcriptase: contribution of Met-184 to binding of nucleoside 5′-triphosphate. Journal of Biological Chemistry 271:13656-13662.
101. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, Lengauer T, Selbig J, Vandamme AM, Korn K & Schmidt B (2003) Tenofovir resistance and resensitization. Antimicrobial Agents & Chemotherapy 47:3478-3484.
102. Yadav A & Singh SK (2004) Threshold interaction energy of NRTI's (2′-deoxy 3′-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition. Bioorganic & Medicinal Chemistry Letters 14:2677-2680.
103. Yoshimura K, Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J & Mitsuya H (1999) In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrobial Agents & Chemotherapy 43:2479-2483.